Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab + docetaxel versus atezolizumab in previously treated PD-L1-negative or weakly positive advanced non-small-cell lung cancer
jRCTs031180363Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Atezolizumab with Docetaxel + ramucirumab (2 arms). Primary endpoint: Overall survival. Started Jun 2018; status: completed.
02
Drugs
ramucirumabdocetaxelatezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031180363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180363.